La science pour la santé _____ From science to health







Liberté Égalité Fraternité

Contents

- Address major biomedical research challenges
- Take action to improve the health of all
- Disseminate knowledge for the benefit of all



Address major biomedical research challenges





Be a reference in biomedical research





in Europe and worldwide

- 6,500 international cooperations with more than 100 countries
- 33 European and international research projects or networks
- 2 Inserm Units



- 263 Research Units
- 34 Clinical Investigation Centers
- 40 Service Units



13,803 staff

- 5,047 civil servants (2,144 researchers, ATIP-Avenir contracts included)
- 3,257 contract staff and temporary workers (incl. ATIP-Avenir contracts)
- > 45 ATIP-Avenir contracts
- 5,499 university-hospital practicioners and university staff

A budget of €993 million

€658 million from government subsidies and €335 million from external resources



Patents and licenses

- A portfolio of 2,069 patent families
- 110 new license agreements signed
- 326 R&D partnerships



Be a reference in biomedical research(2)





Worldwide and in Europe

- 9th most innovative public research organization worldwide in 2019
- No. 1 academic applicant in the biomedical sector and No. 2 in the biotechnology sector in Europe
- · No. 1 European applicant in the pharmaceutical sector

- 384 H2020 contracts, 146 within the Health challenge and 35 coordinated by Inserm (No. 1 in Europe)
- 82 ERC grant recipients
- 45 Marie Skłodowska-Curie individual grants and participation in 44 innovative training networks (ITN)



Close dialogue

with over 500 patient organizations for

- participatory research
- meetings and debates between patients and researchers




13,234 original articles





Make changes to adapt







Our organization

Ethics Committee
Ethics Evaluation Committee
Scientific Integrity Office
Think Tank Network with Patient
Organizations (GRAM)
History Committee

Thematic Institutes



Vice CEO for Strategy Thomas Lombès



Chairman and CEO Gilles Bloch

Directorate General



Vice CEO for Administration Damien Rousset

Management Board

Scientific Advisory Board

Specialized Scientific Committees

Research Support Committee

- Neurosciences, Cognitive Sciences, Neurology, Psychiatry
- Cancer
- Immunology, Inflammation, Infectious Diseases and Microbiology
- Pathophysiology, Metabolism, Nutrition
- Public Health
- Health Technologies
- Molecular and Structural Basis of Living Organisms
- · Cell Biology, Development and Evolution
- · Genetics, Genomics and Bioinformatics

Divisions


- · Financial Affairs
- · Legal Affairs
- · Program Assessment and Follow-Up
- · Scientific Information and Communication
- · Partnership and External Relations
- Human Resources
- · Information Systems
- · Chief Accounting Department

Regional Offices

- Île-de-France (4)
- · Auvergne-Rhône-Alpes
- Est
- · Grand Ouest
- Occitanie Méditerranée
- Occitanie Pyrénées
- Nord-Ouest
- · Nouvelle-Aquitaine
- · Provence, Alpes, Côte d'Azur and Corsica



• Address major biomedical research challenges





• Address major biomedical research challenges

Our presence in France

Sorbonne Université Université de Paris Paris Sciences & Lettres Université Paris-Saclay



Research
universities in
which Inserm
invests more
than €10M
each year

83% of Inserm strengths




Lille





Our main partners



- 34 universities
- A key partner of 14 research universities in which Inserm invests more than €10M each year
- On 15 Idex and I-sites, Inserm invests 77% of its resources
- Research Units in 30 teaching hospitals

- Founding members of Aviesan alongside Inserm: CEA / CNRS / INRAE / INRIA / Institut Pasteur / IRD / CPU / CHRU and the associate members
- Other alliances: AllEnvi, Allistène, Athéna
- Industry: Astra Zeneca/MedImmune, Dassault System 3DS, MSD Avenir, Sanofi...
- Foundations and associations: Fondation Bettencourt Schueller, FRM...
- European and international academic institutions: Helmholtz...



Address major biomedical research challenges

Our presence in Europe

Research unit abroad

CNRS-Inserm International Research Network





- Research teams: informal scientific cooperation with their partners
- Institutional partnership agreements and specific collaborative networks in Europe: 7 European laboratories within the International Research Project (IRP) program and 6 European laboratories within an International Research Network (IRN)





Our presence in the world





- Research teams: informal scientific cooperation with their partners
- Institutional partnership agreements and specific collaborative networks outside Europe: 23 non-European laboratories within the International Research Project (IRP) program and 4 non-European laboratories within 2 International Research Networks (IRN)





Take action to improve the health of all






Our missions for health









for science based policy in health



Create value from discoveries and their applications





INITIATE, DEVELOP AND COORDINATE BIOMEDICAL **RESEARCH OF EXCELLENCE**



Play a major role in the national coordination of health research



Support higher education and research training






• Take action to improve the health of all

Inserm

Our fields of activity and expertise





Cohorts and epidemiological studies







Over 1.6 million people

(2% of the French people) participating in Inserm cohorts

EpiCOV

130.000 volunteers for research on SARS-CoV-2

ELFE

20.000 children born in 2011. Longitudinal study from birth to adult age

Constances

200,000 subjects representative of the French population, aged 18 to 69 years + a biobank of 100,000 subjects

RaDiCo

over 5,000 people with rare diseases in 12 cohorts

Major public health expertise and research

databases. accessible online

Epidemiologie-France portal

French health database catalogue > epidemiologiefrance.aviesan.fr

CépiDc

Epidemiology center on the medical causes of death

> cepidc.inserm.fr

Orphanet

Portal for rare diseases and orphan drugs > orpha.net








• Take action to improve the health of all

A continuum from basic to clinical, therapeutic, and public health research







Value creation activities which are bearing fruit



- 2,069 patent families portfolio
- 147 new patent families in 2020
- An annual budget of €1.4 M to fund project maturation or proof of concept
- A maturation budget reaching €20.3 M invested in 307 projects since 2009
- €408 M industrial partenerships since 2006 incl. €37.3 M in 2020 (1/3 patent licensing, 2/3 research contracts)
- €6-12 M per year from licensing agreements

- Over 400 technologies available for licensing
- Strategic alliances with, for example:
 Astra Zeneca/MedImmune, Dassault System 3DS, MSD Avenir, Sanofi
- 10 start-ups created each year via Inserm Transfert (Inserm's subsidiary)





Partnerships with SATT



Inserm/Inserm Transfert in 2020 rankings








- 1st patent applicant at EPO in pharmaceuticals (5th year)*
- 2nd in the biotechnology sector (1st year)*
- 1st research academic institution in the biomedical sector *
- 2,069 patent families as of 31/12/2020



8th in France all sectors represented



^{*} European Patent Office (EPO) 2020 rankings

Inserm Transfert: partnering with industries



SOME OF OUR INDUSTRIAL PARTNERS: Privileged partner of major industrials, mid-size, SME, involved in human health, at the international level



































SANOFI





















Inserm spin-offs based on inventors as drivers































































































Major discoveries



Since its foundation in 1964, Inserm has played a part in many key, historic medical advances, such as:

- the first prenatal diagnostic tests;
- understanding the HLA system and the ensuing immune reactions;
- the first in vitro fertilization;

- identification of HIV;
- radiotherapy for cancer;
- the first skin graft;
- deep brain stimulation in the treatment of Parkinson's disease;
- gene therapy...



Disseminate knowledge for the benefit of all






• Disseminate knowledge for the benefit of all


Collective expert reviews and contribution to public health policy




Inserm fulfils its mission of expertise provision and knowledge transfer to decision-makers in the field of public health by providing the scientific insight required to take decisions on public health policy issues.













Our work with patient organizations



A mission to forge closer links between Inserm and over 500 patient organizations

- Facilitate access to scientific information for patients through training
- Promote events and direct dialogue between researchers and patient organizations
- Relay the concerns and needs of society to Inserm's management
- Engage for better collaboration of researchers with patient organizations in the evaluation process



Our presence in the service of public information

















10,000 participants

Public events

+ than 1,5 million participants and views



Patient organization training seminars

1,100 participants



Canal Détox, information videos and articles

+ than 1.3 million views





#LaSciencePourLaSanté



